But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

The DMN is responsible for memory and has preferential accumulation of amyloid-beta and tau versus other regions, Koch noted.

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

A new study has used powerful imaging to reveal a subset of Alzheimer's-associated proteins spreading particularly rapidly.

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

This increase correlated with changes in biomarkers associated with neurodegenerative diseases like Alzheimer’s, such as ...